Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides
Graphical abstract
Section snippets
Acknowledgments
The authors would like to thank NIH (U01MH087965, Vanderbilt, NCDDG). We also thank William K. Warren, Jr. and the William K. Warren Foundation who funded the William K Warren, Jr. Chair in Medicine (to C.W.L.).
References (24)
- et al.
Bioorg Med Chem Lett
(2013) - et al.
Bioorg Med Chem Lett
(2012) - et al.
J Biomol Screening
(2015) - et al.
Bioorg Med Chem Lett
(2016) - et al.
Bioorg Med Chem Lett
(2016) - et al.
Bioorg Med Chem Lett
(2017) - et al.
Acc Chem Res
(1998) - et al.
Proc Natl Acad Sci USA
(2008) - et al.
Neuropsychopharmacology
(2010) - et al.
J Pharm Exp Ther
(2008)
Neuropsychopharmacology
Neuropsychopharmacology
Cited by (16)
Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl)pyridine positive allosteric modulators for the M<inf>4</inf> mAChR
2023, European Journal of Medicinal ChemistryStructure–activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M<inf>4</inf>
2023, Acta Pharmaceutica Sinica BCitation Excerpt :Notwithstanding the high affinity and selectivity of VU010010 for M4 receptors, its further development was plagued by solubility issues and P-glycoprotein (P-gp) efflux in vivo29. Other derivatives of the same series include, but are not limited to, VU0152099 and VU0152100 (ML108)30–33, VU046715434,35, VU0409524 (ML293)36, VU600091837, VU044808838, VU602841839 as well as VU0467485 (AZ13713945)40 (Fig. 1), but clinical trials with these compounds have not been reported to date. Indeed, M4-selective targeted therapy is far from routine clinical use and the majority of reported ligands were plagued by inappropriate bioavailability and CNS exposure, high P-gp efflux liability, species variability, and poor metabolic stability or selectivity for M4.
Discovery of structurally distinct tricyclic M<inf>4</inf> positive allosteric modulator (PAM) chemotypes – Part 2
2021, Bioorganic and Medicinal Chemistry LettersDiscovery of structurally distinct tricyclic M<inf>4</inf> positive allosteric modulator (PAM) chemotypes
2020, Bioorganic and Medicinal Chemistry LettersDiscovery of a novel 3,4-dimethylcinnoline carboxamide M<inf>4</inf> positive allosteric modulator (PAM) chemotype via scaffold hopping
2019, Bioorganic and Medicinal Chemistry LettersFour-Membered Ring Systems
2018, Progress in Heterocyclic ChemistryCitation Excerpt :Image Continued chemical optimization of a novel series of muscarinic acetylcholine receptor (M4) positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety 8 is detailed (17BMCL2990). A scaffold hopping exercise identified a novel 2,4-dimethylquinoline-6-carboxamide core in 9 that possesses M4 PAM activity and good central nervous system penetration without an amino moiety (17BMCL4999).